SLC2A4, solute carrier family 2 member 4, 6517

N. diseases: 158; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.040 Biomarker disease BEFREE Palmitic acid (PA)-treated H9c2 cardiomyoblasts and neonatal rat ventricle cardiomyocytes were used to simulate hyperlipidemia model, which suppress cluster of differentiation 36 (CD36) and activate glucose transporter type 4 (GLUT4). 29130531 2018
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.040 Biomarker disease BEFREE In this study, we treated H9c2 cells with PA to create a hyperlipidemia model in vitro and analyzed for CD36 and GLUT4 metabolic pathway proteins. 28500736 2017
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.040 Biomarker disease BEFREE Our findings manifest that EK100 may have therapeutic potential in treating type 2 diabetes associated with hyperlipidemia in HFD-fed mice by regulation of GLUT4, PEPCK, G6 Pase, SREBP1c, SREBP2, apo A-I, and AMPK phosphorylation. 25693659 2015
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.040 AlteredExpression disease LHGDN We propose that HL, exhibited as a high free fatty acid level, modulates GLUT4 gene expression in cardiac muscle via a complex mechanism that includes: (a) binding of AA mediator proteins to three newly identified response elements on the GLUT4 promoter gene and (b) repression of GLUT4 and the PPARgamma genes by AA. 16096283 2005
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.040 AlteredExpression disease BEFREE We propose that HL, exhibited as a high free fatty acid level, modulates GLUT4 gene expression in cardiac muscle via a complex mechanism that includes: (a) binding of AA mediator proteins to three newly identified response elements on the GLUT4 promoter gene and (b) repression of GLUT4 and the PPARgamma genes by AA. 16096283 2005